ReviewClinics (Sao Paulo, Brazil)2014
New immunosuppressive agents in pediatric transplantation.
Review in Clinics (Sao Paulo, Brazil), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Network pharmacology-based analysis of the role of tacrolimus in liver transplantation.Saudi journal of biological sciences · 2021Article
- A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept.Indian journal of thoracic and cardiovascular surgery · 2020Review
- Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities.International journal of molecular sciences · 2019Review
- Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures.Pediatric transplantation · 2018Article
- Pulmonary hypertension and cardiac hypertrophy in children recipients of orthotopic living related liver transplantation.Journal of advanced research · 2017Article
- Blood disorders typically associated with renal transplantation.Frontiers in cell and developmental biology · 2015Review
- Common challenge topics in pediatric transplantation.Clinics (Sao Paulo, Brazil) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressive therapy in pediatrics continues to evolve. Over the past decade, newer immunosuppressive agents have been introduced into adult and pediatric transplant patients with the goal of improving patient and allograft survival. Unfortunately, large-scale randomized clinical trials are not commonly performed in children. The purpose of this review is to discuss the newer immunosuppressive agents available for induction therapy, maintenance immunosuppression, and the treatment of rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.